Bausch Health (BHC) | Stock Overview & Key Data
Bausch Health Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $263.81 on August 3, 2015
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Bausch Health
BHC
|
2.10B Mid-cap | -2.35% | -7.93% | -0.80% | -27.79% | -30.79% | -15.38% | -31.16% | -82.74% | -77.04% | -89.99% | -77.64% |
|
Zoetis
ZTS
|
49.75B Large-cap | 0.16% | 3.42% | -31.08% | -32.94% | -36.81% | -51.58% | -53.40% | -57.08% | 71.34% | 156.59% | 156.59% |
|
Haleon Plc - ADR
HLN
|
42.40B Large-cap | 2.02% | 1.23% | -13.29% | -7.73% | -9.30% | -16.01% | 8.43% | 23.21% | 23.21% | 23.21% | 23.21% |
|
Alkermes plc
ALKS
|
5.55B Mid-cap | 4.50% | 18.36% | 58.43% | 57.47% | 56.97% | 48.44% | 37.56% | 81.33% | 7.03% | 166.59% | 137.55% |
|
Lantheus Holdings
LNTH
|
5.39B Mid-cap | 4.66% | 11.46% | 33.34% | 57.23% | 55.60% | 34.29% | 18.41% | 324.53% | 3,800.00% | 1,525.51% | 1,525.51% |
|
Amneal
AMRX
|
4.15B Mid-cap | 18.45% | 36.13% | 36.01% | 30.34% | 28.28% | 109.03% | 497.79% | 211.54% | 10.20% | 10.20% | 10.20% |
Ownership & Short Interest
Calculate Your Bausch Health Investment Returns
Long-Term Investment Performance Analysis
Bausch Health stock price in Jul 2016 was $22.82, A $1,000.00 lump sum investment in Bausch Health made 9 years ago would be worth approximately $218.67 today, representing a negative return of -78.13%. This translates to an annualized return (CAGR) of -14.22%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is BHC's 52-week high and low?
- In the last 52 weeks, Bausch Health reached a high of $8.69 (on August 15, 2025) and a low of $4.93 (on March 24, 2026).
- What is the market cap and P/E ratio for BHC?
- Curious about Bausch Health's size and valuation? Its market capitalization stands at 2.10B. When it comes to valuation, the P/E ratio (trailing twelve months) is 13.19, and the forward P/E (looking ahead) is 1.37.
- Does BHC pay dividends? If so, what's the yield?
- As for dividends, Bausch Health isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Bausch Health's main competitors or similar companies to consider before investing?
When looking at Bausch Health, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS49.75B Healthcare Drug Manufacturers - Specialty & Generic -51.58% -53.40% Haleon Plc - ADR
HLN42.40B Healthcare Drug Manufacturers - Specialty & Generic -16.01% 8.43% Alkermes plc
ALKS5.55B Healthcare Drug Manufacturers - Specialty & Generic 48.44% 37.56% Lantheus Holdings
LNTH5.39B Healthcare Drug Manufacturers - Specialty & Generic 34.29% 18.41% Amneal
AMRX4.15B Healthcare Drug Manufacturers - Specialty & Generic 109.03% 497.79% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Bausch Health Companies Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Bausch Health's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 436.36%, the Debt to Equity ratio from the most recent quarter is 5,591.25, and its Gross Profit Margin stands at 71.46%.
- What is the recent revenue and earnings growth for BHC?
- Looking at Bausch Health's growth, its revenue over the trailing twelve months (TTM) was $10B. Compared to the same quarter last year (YoY), quarterly revenue grew by 9.30%, and quarterly earnings saw a YoY growth of N/A.
- How much of BHC stock is held by insiders and institutions?
- Wondering who owns Bausch Health stock? Company insiders (like executives and directors) hold about 30.41% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 65.20%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.